Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.
AskGene Pharma is a biotechnology firm. It is developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease. It is unlocking the full therapeutic potential of cytokine molecules with their innovative smart kine prodrug platform. It overcomes a number of significant challenges, providing a clear pathway to a range of next-generation cytokine therapies. They provide safer and better medicines for saving patients’ lives. They are equipped with the most advanced R&D facilities.
SilaGene, Inc. is a biotechnology company based in Hillsborough, New Jersey, founded in 2008. The company specializes in the development of U1 adaptors that hold therapeutic potential for various diseases, particularly in the treatment of different types of cancers. Its innovative technology serves as a gene silencing tool, which enhances the research of gene function in both cell cultures and in vivo settings. By addressing the limitations of existing gene silencing technologies, SilaGene aims to provide effective treatment options for patients.
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Sinogen Biopharma is a biotechnology company dedicated to connecting China's innovative drug development with the pharmaceutical market in the United States. The company specializes in the licensing and development of bacterial carrier-based biological anti-tumor drugs aimed at treating malignant tumors, particularly in the area of metastatic tumors and rare diseases. By focusing on the creation of innovative anti-cancer therapies, Sinogen Biopharma seeks to address the needs of both domestic and international pharmaceutical markets.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
Genevide is a biotech company founded in 2019 and based in Suzhou, Jiangsu, China, focusing on gene research and development. The company has developed a molecular enzyme cycle screening platform designed to address challenges in nucleic acid detection. Its key technologies include enzyme-mediated one-step sample processing and enzyme-mediated double exponential amplification, which facilitate efficient nucleic acid detection for researchers. Genevide aims to provide innovative solutions that make nucleic acid detection more accessible and effective.
PlusLife Biotech is devoted to developing revolutionary molecular diagnostic tools and gene treatment programs employing a new generation of gene technology. Founded in 2017 and is based in Guangzhou, China.
Abogen Biosciences
Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.
Abogen Biosciences
Series B in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Basecamp Bio is a cell and gene therapy research and development company that develops cell and gene therapies, regenerative medicine, and immunotherapies.
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
Genor BioPharma Co., Ltd. is a biopharmaceutical company based in Shanghai, China, established in 2007. The company specializes in the development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion protein drugs, focusing on oncology, autoimmune diseases, and metabolic conditions. Genor BioPharma is actively advancing a diverse pipeline of over ten products, with ten candidates currently in clinical development. Its key drug candidates include GB491, an oral CDK4/6 inhibitor, GB221, a novel HER2 mAb, and geptanolimab, among others. The company aims to address significant unmet medical needs in its therapeutic areas. Genor has also formed a strategic collaboration with Ascentage Pharma to enhance its research and development capabilities.
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
OriGene Technologies, Inc. specializes in the development, manufacturing, and sale of genome-wide research and diagnostic products tailored for academic, pharmaceutical, and biotechnology applications. Founded with a focus on creating a comprehensive collection of full-length human cDNAs, the company offers a diverse range of products, including cDNA clones, shRNA and siRNA tools, and CRISPR/Cas9 genome editing products. Additionally, OriGene provides proteins and lysates, an extensive array of antibodies for immunohistochemistry, and various assay kits, including ELISA and luminex kits. The company supports critical biological research by supplying essential resources for cancer biomarker studies, stem cell research, and other areas. With a commitment to facilitating gene-based research, OriGene distributes its products globally through distributors and online channels. Established in 1995 and based in Rockville, Maryland, OriGene continues to enhance its offerings to meet the evolving needs of researchers in the life sciences field.
Tellgen Corporation, founded in 2003 and based in Shanghai, China, is a biotechnology company specializing in the research, development, manufacturing, and distribution of in vitro diagnostic devices (IVDs). The company offers a variety of products aimed at the detection of tumors and infectious diseases, including tumor markers, human papillomavirus test kits, and Y chromosome microdeletion detection kits. Its portfolio also includes real-time PCR systems, autoimmune antibody tests, and multiplex immunoassay systems. Tellgen's innovations cater to various medical fields, such as tumor detection, cervical cancer screening, DNA methylation detection, male infertility, and prenatal and postnatal care, serving both domestic and international markets.
Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. supplies biochemical research products and services. Its products include biochemicals, aminoacid, antibiotics, biological and electrophoresis buffers, blotting paper and membranes, medium, dyes and indicators, molecular biology kits, PCR related products, restriction endonuclease, DNA and RNA modified enzymes, DNA vector, labwares, and small instruments, as well as RNA, DNA, and protein markers. The company also provides DNA synthesis and sequencing, as well as gene and peptide synthesis. It offers products through distributors in China, Africa, and South America. The company was founded in 1995 and is based in Shanghai, China.